logo-loader
viewRathdowney Resources Ltd

Rathdowney set to reap rewards of zinc price gains at Project Olza

Rathdowney Resources says that with its Project Olza in Poland the zinc miner is well-placed to mitigate the looming squeeze on zinc supply, as it reported fiscal 2015 results

Glencore-zinc-lead_opt.jpg
On the right road in Poland

Rathdowney Resources (CVE:RTH) said on Monday that with its Project Olza in Poland the zinc miner is well-placed to mitigate the looming squeeze on zinc supply, as it reported fiscal 2015 results.

"With Project Olza, Rathdowney is among a short list of junior exploration companies that are well placed in terms of location and stage in the development pipeline to help mitigate this looming squeeze in the zinc supply," the company said.

Although forecasters had predicted that declining zinc production would boost prices further in 2015 and 2016, prices were variable to improving in the first half of 2015, then decreased in the latter part of the year. Prices have been variable to improving so far in 2016.  Recent closing price is USD0.84/lb, the company added.

For the year to December 31, 2015, Rathdowney recorded a loss for the year of C$7.4mln, which is up from C$5.9mln in 2014 but lower than C$8.8mln in 2013.

The increase in 2015 was mainly due to an impairment in the company's holdings of marketable securities, and an increase in drilling and shareholder communications activities, the firm said.

The basic and diluted loss per share was maintained at C$0.06 as in 2014.

Quick facts: Rathdowney Resources Ltd

Price: 0.1 CAD

TSX-V:RTH
Market: TSX-V
Market Cap: $16.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 15 hours ago

2 min read